INNOVYOS

Sodium Hyaluronate plus Niacinamide

THE FIRST *VISCO-BOOSTER* FOR OSTEOARTHRITIS PATIENTS

Concentration	2.2 % Hyaluronic acid + 1.5 % Niacinamide
Molecular weight	1.2–2.2 MDa
Viscosity (mPas)	370 000
Volume	2.0 ml
Forms of therapy	1 to 5 injections
Storage	2–25 °C
Shelf life	42 months

by ALBOMED

INNORYOS

ALBOMED developed INNORYOS, a premium product to maximize the treatment of osteoarthritis.

The combination of hyaluronic acid and niacinamide provides a dual effect for outstanding outcomes. This innovative formulation offers unique antioxidant properties with reinforced resistance to free radical degradation compared to linear and cross linked hyaluronic acid.

It has been proven that niacinamide stimulates extra cellular matrix to provide a better cartilage protection. Thanks to a high quality hyaluronic acid and niacinamide, the relief of osteoarthritis patients is optimized in terms of pain relief and mobility recovery.

DUAL EFFECT

HYALURONIC ACID

Optimal lubrication

Shock absorbing[1]

Restores viscoelastic properties of healthy joint fluid

+

NIACINAMIDE

Antioxidative effect[2]

Limits inflammation[3]

Stimulates synthesis of extracellular matrix[4]

ALBOMED GmbH
Hildebrandstrasse 11
90592 Schwarzenbruck | Germany
Phone: +49 (0) 9183 95 69 82-0
info@innoryos.com | www.innoryos.com

***VISCO-BOOSTER** – THE FIRST INTRA-ARTICULAR INJECTION MADE OF HYALURONIC ACID AND NIACINAMIDE*

References:
1 Hummer, C.D., Angst, F., Ngai, W. et al. High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord 21, 702 (2020). https://doi.org/10.1186/s12891-020-03729-w
2 Ogata S, Takeuchi M, Teradaira S, Yamamoto N, Iwata K, Okumura K, Taguchi H. Radical scavenging activities of niacin related compounds. Biosci Biotechnol Biochem. 2002 Mar;66(3):641-5. doi: 10.1271/bbb.66.641. PMID: 12005062
3 Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996 Jul; 45(7):330-4. doi: 10.1007/BF02252945. PMID: 8841834
4 Atlantic Bone Screen, assigned by ALBOMED GmbH. In-vitro evaluation of the anti-hypertrophic effect of 1 product on rat chondrocytes. 2019

V0.2 Art. No. 05065